Intellia Therapeutics Q1 FY25: revenue $16.6M, down 43%; diluted EPS −$1.10

Key figures from this report

These are the numbers Intellia Therapeutics reported for Q1 FY25, the quarter ended Mar 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Revenue$16.6M−43% from $28.9M in Q1 FY2410-Q income statement, on EDGAR
2. Net income−$114.3MAgainst −$107.4M in Q1 FY2410-Q income statement, on EDGAR
3. Diluted EPS−$1.10Against −$1.12 in Q1 FY2410-Q income statement, on EDGAR
4. Cash and cash equivalents$126.9M−26% from $172.0M in Q1 FY24Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
5. Cash from operations−$148.9MAgainst −$120.7M in Q1 FY2410-Q cash flow statement, on EDGAR

Every quarter in the financial tables